Finally, Côte et al. show that depleting CD8+ cells together with the administration of anti-GITR Ab, at the time of inducing the primary tumor, significantly reduces the number of mice rejecting secondary tumors [67]. The gene discussed is CD8A; the disease is neoplasm.